Treatment strategies for diabetic patients suffering from erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 257-266

  Chen, Yun ^a   Dai, Yutian ^a   Wang, Run ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Erectile dysfunction; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALKALOID DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; APOMORPHINE; CYCLIC GMP; GINSENG EXTRACT; INSULIN; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLANT EXTRACT; PROPIONYLCARNITINE; PROSTAGLANDIN E1; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; UDENAFIL; VARDENAFIL; VASOACTIVE AGENT;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; HYPERGLYCEMIA; HYPOGONADISM; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PENIS PROSTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SUPPOSITORY; THROMBOCYTE AGGREGATION INHIBITION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES COMPLICATIONS; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE PROSTHESIS; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 39049103785     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.257     Document Type: Review

References (98)

1. Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9
2. Khatib FA, Jarrah NS, Shegem NS, et al. Sexual dysfunction among Jordanian men with diabetes. Saudi Med J 2006;27:351-6
3. Sasaki H, Yamasaki H, Ogawa K, et al. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9
4. Klein R, Klein BE, Moss SE. Ten-year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes. J Diabetes Complications 2005;19:35-41
5. Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep 2002;2:60-6
6. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006;8:675-84
7. Podlasek CA, Zelner DJ, Bervig TR, et al. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001;166:746-55
8. Hecht MJ, Neundorfer B, Kiesewetter F, et al. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res 2001;23:651-4
9. Chen Y, Yang R, Yao L, et al. Differential expression of neurotrophins in penises of streptozotocin-induced diabetic rats. J Androl 2007;28:306-12
10. Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005;173:1820-4
11. Angulo J, Cuevas P, Gabancho S, et al. Enhancement of both EDHF and NO/ cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. J Sex Med 2005;2:341-6
12. Shirai M, Yamanaka M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun 2006;341:755-62
13. Park CS, Ryu SD, Hwang SY. Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats. J Ethnopharmacol 2004;94:85-92
14. Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003;169:1911-7
15. Escrig A, Marin R, Abreu P, et al. Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 2002;66:185-9
16. Yildirim S, Ayan S, Sarioglu Y, et al. The effects of long-term oral administration of L-arginine on the erectile response of rabbits with alloxan-induced diabetes. BJU Int 1999;83:679-85
17. Ari G, Vardi Y, Finberg JP. Nitric oxide and penile erection in streptozotocin-diabetic rats. Clin Sci 1999;96:365-71
18. Simopoulos DN, Gibbons SJ, Malysz J, et al. Corporeal structural and vascular micro architecture with X-ray micro computerized tomography in normal and diabetic rabbits: histopathological correlation. J Urol 2001;165:1776-82
19. Lu YL, Shen ZJ, Wang H, et al. Ultrastructural changes of penile tunica albuginea in diabetic rats. Asian J Androl 2004;6:365-8
20. Angulo J, Cuevas P, Fernandez A, et al. Enhanced thromboxane receptor-mediated responses and impaired endothelium-dependent relaxation in human corpus cavernosum from diabetic impotent men: role of protein kinase C activity. J Pharmacol Exp Ther 2006;319:783-9
21. Chen Y, Li SX, Yao LS, et al. Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res 2007;19:366-70
22. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7
23. Alexopoulou O, Jamart J, Maiter D, et al. Erectile dysfunction and lower androgenicity in type 1 diabetic patients. Diabetes Metab 2001;27:329-36
24. Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005;2:187-97; discussion 197-8
25. Ryu JK, Lee T, Kim DJ, et al. Free radical-scavenging activity of Korean red ginseng for erectile dysfunction in non-insulin-dependent diabetes mellitus rats. Urology 2005;65:611-5
26. De Young L, Yu D, Bateman RM, et al. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004;25:830-6
27. Usta MF, Kendirci M, Gur S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006;3:242-50; discussion 250-2
28. Usta MF, Bivalacqua TJ, Yang DY, et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003;170:1437-42
29. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001;87:402-7
30. Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997;50:1016-26
31. Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/ Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007;4:620-30; discussion 631-2
32. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004;101:9121-6
33. Hipp JD, Davies KP, Tar M, et al. Using gene chips to identify organ-specific, smooth muscle responses to experimental diabetes: potential applications to urological diseases. BJU Int 2007;99:418-30
34. Davies KP, Zhao W, Tar M, et al. Diabetes-induced changes in the alternative splicing of the Slo gene in corporal tissue. Eur Urol 2007;52:1229-37
35. Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1544-53
36. Abdelbaky TM, Brock GB, Huynh H. Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. Endocrinology 1998;139:3143-7
37. Usta MF, Bivalacqua TJ, Koksal IT, et al. The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int 2004;94:429-32
38. Shirai M, Yamanaka M, Shiina H, et al. Androgen, estrogen, and progesterone receptor gene regulation during diabetic erectile dysfunction and insulin treatment. Urology 2004;64:1244-9
39. Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 2000;53:1011-8
40. Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther 2000;26:133-40
41. Eardley I, Gentile V, Austoni E, et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004;94:871-7.
42. Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15:821-5
43. Israilov S, Shmuely J, Niv E, et al. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005;17:431-6
44. Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005;17:264-9
45. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18:205-10
46. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6
47. Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006;22:2111-20
48. Boulton AJ, Selam JL, Sweeney M, et al. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001;44:1296-301
49. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84
50. Dietz U, Tries HP, Merkle W, et al. Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction. Dtsch Med Wochenschr 2003;128:190-5
51. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
52. Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 120-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006;13:1066-72
53. Ziegler D, Merfort F, Van Ahlen H, et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-91
54. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23
55. Buvat J, Van Ahlen H, Schmitt H, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs, on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006;3:512-20
56. Kang KK, Choi SM, Ahn GJ, et al. The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits. Urol Res 2004;32:107-11
57. Ahn GJ, Sohn YS, Kang KK, et al. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res 2005;17:134-41
58. Yu JY, Kang KK, Yoo M, et al. Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor. Int J Urol 2005;12:299-304
59. Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005;28:260-6
60. Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004;27:114-19
61. Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005;47:87-91
62. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20; discussion 220-2
63. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200-7
64. Schafer A, Fraccarollo D, Pfortscj S, et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 2007
65. Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64.
66. Kalinchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9
67. Zhang XH, Filippi S, Morelli A, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006;3:253-64; discussion 264-5, author reply 265-6
68. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9
69. Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res 2005;17:80-5
70. De Young L, Yu D, Freeman D, et al. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003;15:347-54
71. Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-84
72. Morano S, Mandosi E, Fallarino M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 52(6):1768-76
73. Vrijhof HJ, Delaere KP. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology. Br J Urol 1994;74:102-5
74. Price DE, Cooksey G, Jehu D, et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991;8:964-7
75. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938
76. Broderick GA, Lue TF. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology, 8th ed. Philadelphia: Saunders Publishers; 2002. p. 1619-71
77. Bell DS, Cutter GR, Hayne VB, et al. Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. Urology 1992;40:36-40
78. Lane BR, Ausmundson SJ, Butler RS, et al. Use of a visual analog scale to assess pain of injection with intracavernous injection therapy. J Sex Med 2005;2:428-31
79. Perimenis P, Gyftopoulos K, Athanasopoulos A, et al. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001;40:398-402; discussion 403
80. Lepore G, Nosari I. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. Diabetes Care 2001;24:409-11
81. Perimenis P, Markou S, Gyftopoulos K, et al. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002;41:387-91
82. Fedele D, Coscelli C, Cucinotta D, et al. Management of erectile dysfunction in diabetic subjects: results from a survey of 400 diabetes centres in Italy. Diabetes Nutr Metab 2001;14:277-82
83. Heaton JP, Lording D, Liu SN, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13:317-21
84. Perimenis P, Konstantinopoulos A, Perimeni PP, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006;8:219-24
85. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7
86. Li MK, Lim PH, Wong MY, et al. Transurethral alprostadil for the treatment of erectile dysfunction: results of a multicentre trial. Ann Acad Med Singapore 2000;29:727-31
87. Carrion H, Bakshandeh K, Rodriguez A, et al. Small-Carrion penile prosthesis for the management of diabetic impotence. South Med J 1980;73:310-1
88. Jaworski TM, Richards JS, Lloyd LK. Retrospective review of sexual and marital satisfaction of spinal cord injury and diabetic males post penile injection or implant. Urology 1992;40:127-31
89. Peterson HR, Best JD, Berger R, et al. Attitudes of diabetic men after implantation of a semi-rigid penile prosthesis. Diabetes Care 1985;8:156-60
90. Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol 2006;176:2471-3
91. Bishop JR, Moul JW, Sihelnik SA, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992;147:386-8
92. Wilson SK, Carson CC, Cleves MA, et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998;159:1537-9; discussion 1539-40
93. Dai YT, Chen Y, Yao LS, et al. Expression of nerve growth factor in cavernous tissue and its effects on the treatment of rats with diabetic erectile dysfunction. Zhonghua Nan Ke Xue 2005;11:748-51, 54
94. Shen ZJ, Wang H, Lu YL, et al. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005;95:890-4
95. Jesmin S, Zaedi S, Yamaguchi N, et al. Effects of dual endothelin receptor antagonist on antiapoptotic marker Bcl-2 expression in streptozotocin-induced diabetic rats. Exp Biol Med (Maywood) 2006;231:1034-9
96. Anaka M, Shirai M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005;173:318-23
97. Tong YC, Hung YC, Lin SN, et al. Treatment effect of "ryu-wei-ti-huang-wan" (a Chinese herbal prescription) on the sexual performance of male rats with streptozotocin-induced diabetes. Urol Int 1996;57:230-4
98. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30